Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by Walterthedogon Oct 13, 2021 10:22am
257 Views
Post# 34000715

RE:Bud/Offer

RE:Bud/OfferPeople are tired of the CEO leading them along with a carrot on a string. I strongly believe he is either unable to finish the trial or they know the results are sh1t. It's the only thing that can explain the stalling and change of focus from the completion of the trial to dodging questions about it and proposing we start multiple new trials. Complete reversal in game plan. What used to be talk of commercializing in Asia has been completely ditched. But still he tells us it will be complete this year when he knows it wont to keep his few remaining holders hooked. Maybe i'm wrong but that's how this looks to me. He's also spoken recently about a business opportunity that will allow us to run multiple trials in parallel. That would be an enormous investment and seems like another carrot on a stick to me but who knows. Good luck fellas. Stay tuned for more nothing would be my guess
<< Previous
Bullboard Posts
Next >>